Quantcast

Monday, August 30, 2010

Novartis receives FDA approval of Tekamlo, a single-pill combination of aliskiren and amlodipine to treat high blood pressure

The US Food and Drug Administration (FDA) approved Tekamlo (aliskiren and amlodipine) tablets, a single-pill for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna (aliskiren), with the widely used calcium channel blocker amlodipine. Since Aliskiren is already in the market, it needs to be seen which one of the 3 classes of drugs tergeting the renin-angiotensin-aldosterone system (angiotensin receptor blockers, ACE inhibitors and renin inhibitors) is a better alternative for hypertensive patients. In our medical school we are initiating a trial comparing newer angiotensin receptor blockers and ACE inhibitors. I do not know whether aliskiren is available in India and at what cost.

Novartis receives FDA approval of Tekamlo, a single-pill combination of aliskiren and amlodipine to treat high blood pressure

Free Books, powerpoint presentations, teaching tools and resources and drug information